High stakes: Eli Lilly’s hunt for an Alzheimer’s drug
On Wednesday, the pharma giant learnt that Sola — a drug it hoped would slow the progression of the disease — had failed its phase III trial. Before that, David Crow reported on the company’s long search for a cure
On Wednesday, the pharma giant learnt that Sola — a drug it hoped would slow the progression of the disease — had failed its phase III trial. Before that, David Crow reported on the company’s long search for a cure